<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2588-0519-2021-3-50-56</article-id><article-id custom-type="elpub" pub-id-type="custom">clinvest-586</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL PHARMACOLOGY</subject></subj-group></article-categories><title-group><article-title>Оценка приверженности больных фибрилляцией предсердий к антикоагулянтной терапии на амбулаторном этапе лечения</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2220-7726</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Соколов Алексей Владимирович, ассистент кафедры фармакологии </p><p>SPIN-код: 7822-8424 </p><p>Саратов</p></bio><bio xml:lang="en"><p>Sokolov Alexey V., Assistant of the Department of Pharmacology </p><p>SPIN code: 7822-8424</p><p>Saratov</p></bio><email xlink:type="simple">sokolovalexsej@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7401-9930</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Липатова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Lipatova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Липатова Татьяна Евгеньевна, д. м. н., профессор, заведующий кафедрой терапии с курсами кардиологии, функциональной диагностики и гериатрии </p><p>SPIN-код: 2483-3578</p><p>Саратов</p></bio><bio xml:lang="en"><p>Lipatova Tatiana E., Dr. Sci. (Med.), Professor, Head of Department of Therapy with Сourses of Сardiology, Functional Diagnostics and Geriatrics </p><p>SPIN code: 2483-3578</p><p>Saratov</p></bio><email xlink:type="simple">lipatova.t@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3107-7636</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетько</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetko</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Решетько Ольга Вилоровна, д. м. н., профессор, зав. кафедрой фармакологии</p><p>SPIN-код: 7569-7915 </p><p>Саратов</p></bio><bio xml:lang="en"><p>Reshetko Olga V., Dr. Sci. (Med.), Professor, Head of Department of Pharmacology  </p><p>SPIN code: 7569-7915</p><p>Saratov</p></bio><email xlink:type="simple">reshetko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Саратовский ГМУ им. В. И. Разумовского Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saratov State Medical University named after V. I. Razumovsky Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>12</month><year>2021</year></pub-date><volume>0</volume><issue>3</issue><fpage>50</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Соколов А.В., Липатова Т.Е., Решетько О.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Соколов А.В., Липатова Т.Е., Решетько О.В.</copyright-holder><copyright-holder xml:lang="en">Sokolov A.V., Lipatova T.E., Reshetko O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/586">https://www.clinvest.ru/jour/article/view/586</self-uri><abstract><p>В реальной клинической практике приверженность пациентов с фибрилляцией предсердий (ФП) к оральным антикоагулянтам (ОАК) остаётся на низком уровне, несмотря на наличие клинических рекомендаций. Оценка факторов, влияющих на соблюдение режима приёма ОАК, и разработка стратегий по его улучшению является важной задачей. Цель. Оценить приверженность больных ФП к назначенной антикоагулянтной терапии на амбулаторном этапе лечения. Методология. Объектом исследования являлись 165 больных ФП, находившихся на лечениив специализированном кардиологическом отделении одной из муниципальных больниц г. Саратова или получавших амбулаторное лечение у врача-кардиолога в кардиологическом диспансере с февраля 2018 по декабрь 2019 г. Через 3, 6, 12 месяцев с пациентами устанавливался телефонный контакт, в ходе которого заполнялась анкета, в которой отражалась получаемая на тот момент антикоагулянтная терапия, проводилась оценка приверженности с применением опросника Мориски-Грина, фиксировались ответы пациентов о причинах пропуска или прекращения приёма ОАК.Результаты. Через 3 мес. наблюдения 16,6 % больных ФП заменили приём ОАК антиагрегантами, 16 % отказались от антитромботической терапии. Приверженными к терапии ОАК были признаны 43,1 % больных ФП. Через 6 мес. антиагреганты принимали 24,5 % (p&lt;0,05), 11,9 % прекратили приём антитромботических препаратов; приверженными терапии ОАК были 30,8 % больных (p&lt;0,05). Через 12 мес. замену ОАК антиагрегантами произвели 29,5 % больных ФП, 7,6 % не принимали антитромботические препараты; 31,8 % больных ФП являлись приверженными к приёму ОАК. Наиболее частыми причинами снижения приверженности к терапии ОАК являлись стоимость данных препаратов, непонимание значения приёма ОАК при ФП и отсутствие ощутимого эффекта от приёма ОАК. Заключение. На амбулаторном этапе лечения отмечался недостаточный уровень приверженности больных ФП к терапии ОАК.</p></abstract><trans-abstract xml:lang="en"><p>Despite clinical guidelines for the treatment of atrial fibrillation (AF) patient adherence to oral anticoagulants (OACs) in routine clinical practice remains low. Assessing the factors affecting adherence to the OACs regimen and developing strategies for its improvement is important. Aim. To assess the adherence of patients with AF to the prescribed anticoagulant therapy at the outpatient stage of treatment. Methodology. The object of the study was 165 patients with nonvalvular AF undergoing treatment in a specialized cardiology department or receiving outpatient treatment in a specialized cardiological dispensary in Saratov from February 2018 to December 2019. After 3, 6, 12 months, a telephone contact with the patients was carried out, a specially designed questionnaire was filled out, in which the anticoagulant therapy received by AF patients was reflected, the Morisky-Green questionnaire was filled out, the answers of patients about the reasons for skipping or stopping the administration of the OACs were recorded. Results. After 3 months. 16.6 % of AF patients replaced the OACs intake with antiplatelet agents, 16 % refused antithrombotic therapy; 43.1 % of AF patients were adherent to OACs. After 6 months. antiplatelet agents were taken by 24.5 % patients (p&lt;0.05), 11.9 % completely stopped taking antithrombotic drugs; 30.8 % of patients were adherent to OACs (p&lt;0.05). After 12 29,5 % patients replaced OACs treatment with antiplatelet agents, 7.6 % patients did not take any antithrombotic drugs; 31.8 % of AF patients were adherent to OACs. The most common reasons for a decrease in the adherence to OACs therapy were the cost of drugs, lack of understanding of the value of OACs administration in AF, and the lack of appreciable effect of OACs administration. Conclusion. At the outpatient stage of treatment, there was an insufficient level of adherence of AFpatients to OACs treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>антикоагулянтная терапия</kwd><kwd>приверженность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>anticoagulant therapy</kwd><kwd>adherence</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russian Journal of Cardiology. 2017;(7):7–86. doi: 15829/1560-4071-2017-7-7-86</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russian Journal of Cardiology. 2017;(7):7–86. doi: 15829/1560-4071-2017-7-7-86</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323. doi: 10.1016/S1474-5151(03)00091-4</mixed-citation><mixed-citation xml:lang="en">Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323. doi: 10.1016/S1474-5151(03)00091-4</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185(2):E121–7. doi: 10.1503/cmaj.121218</mixed-citation><mixed-citation xml:lang="en">Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185(2):E121–7. doi: 10.1503/cmaj.121218</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Raparelli V, Proietti M, Buttа C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9(8):861—70. doi: 10.1007/s11739-014-1096-1</mixed-citation><mixed-citation xml:lang="en">Raparelli V, Proietti M, Buttа C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9(8):861—70. doi: 10.1007/s11739-014-1096-1</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kimmel SE, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study Arch Intern Med. 2007;167(3):229–35. doi: 10.1001/archinte.167.3.229</mixed-citation><mixed-citation xml:lang="en">Kimmel SE, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study Arch Intern Med. 2007;167(3):229–35. doi: 10.1001/archinte.167.3.229</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6(9):1500–6. doi: 10.1111/j.1538-7836.2008.03059.x</mixed-citation><mixed-citation xml:lang="en">Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6(9):1500–6. doi: 10.1111/j.1538-7836.2008.03059.x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–31. doi: 10.1161/CIRCOUTCOMES.110.937680</mixed-citation><mixed-citation xml:lang="en">Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–31. doi: 10.1161/CIRCOUTCOMES.110.937680</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">O’Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014; 168(4):487–94. doi: 10.1016/j.ahj.2014.07.002</mixed-citation><mixed-citation xml:lang="en">O’Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014; 168(4):487–94. doi: 10.1016/j.ahj.2014.07.002</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015;17(12):1747–69. doi: 10.1093/europace/euv233</mixed-citation><mixed-citation xml:lang="en">Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015;17(12):1747–69. doi: 10.1093/europace/euv233</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. doi: 10.1093/eurheartj/ehs253</mixed-citation><mixed-citation xml:lang="en">Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. doi: 10.1093/eurheartj/ehs253</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429</mixed-citation><mixed-citation xml:lang="en">Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Atrial Fibrillation: The Management of Atrial Fibrillation — PubMed — NCBI [Internet]. [cited 2021 September 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=25340239</mixed-citation><mixed-citation xml:lang="en">Atrial Fibrillation: The Management of Atrial Fibrillation — PubMed — NCBI [Internet]. [cited 2021 September 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=25340239</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Левитан А. И., Решетько О. В. Оценка приверженности больных с ревматоидным артритом медикаментозному лечению. Фармакоэкономика: теория и практика. 2016;4(1):213. [Levitan AI, Reshetko OV. Adherence to drug therapy on rheumatoid arthritis. Farmakoekonomika: teoriya i praktika. 2016;1(4):213. (In Russ).]</mixed-citation><mixed-citation xml:lang="en">Левитан А. И., Решетько О. В. Оценка приверженности больных с ревматоидным артритом медикаментозному лечению. Фармакоэкономика: теория и практика. 2016;4(1):213. [Levitan AI, Reshetko OV. Adherence to drug therapy on rheumatoid arthritis. Farmakoekonomika: teoriya i praktika. 2016;1(4):213. (In Russ).]</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Левитан А. И., Решетько О. В. Реальная клиническая практика фармакотерапии ревматоидного артрита. Клиническая фармакология и терапия. 2019;28(1):44–9. [Levitan AI, Reshetko OV. Treatment of rheumatoid arthritis in the real-life practice. Clin Pharmacol Therapy. 2019;28(1):44–9. (In Russ).]. doi: 10.32756/0869-5490-2019-1-44-49</mixed-citation><mixed-citation xml:lang="en">Левитан А. И., Решетько О. В. Реальная клиническая практика фармакотерапии ревматоидного артрита. Клиническая фармакология и терапия. 2019;28(1):44–9. [Levitan AI, Reshetko OV. Treatment of rheumatoid arthritis in the real-life practice. Clin Pharmacol Therapy. 2019;28(1):44–9. (In Russ).]. doi: 10.32756/0869-5490-2019-1-44-49</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. doi: 10.1056/NEJMoa0905561</mixed-citation><mixed-citation xml:lang="en">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. doi: 10.1056/NEJMoa0905561</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. doi: 10.1056/NEJMoa1009638</mixed-citation><mixed-citation xml:lang="en">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. doi: 10.1056/NEJMoa1009638</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981– 92. doi: 10.1056/NEJMoa1107039</mixed-citation><mixed-citation xml:lang="en">Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981– 92. doi: 10.1056/NEJMoa1107039</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. doi: 10.1056/NEJMoa1310907</mixed-citation><mixed-citation xml:lang="en">Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. doi: 10.1056/NEJMoa1310907</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi: 10.1056/NEJMoa1007432</mixed-citation><mixed-citation xml:lang="en">Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi: 10.1056/NEJMoa1007432</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yao X. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. doi: 10.1161/JAHA.115.003074</mixed-citation><mixed-citation xml:lang="en">Yao X. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. doi: 10.1161/JAHA.115.003074</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
